Company Filing History:
Years Active: 2011-2016
Title: Innovations by Fred R. Hirsch in Cancer Treatment
Introduction
Fred R. Hirsch is a notable inventor based in Denver, CO, who has made significant contributions to the field of cancer research. He holds 2 patents that focus on improving the treatment outcomes for patients with non-small cell lung cancer. His work is particularly relevant in the context of epidermal growth factor receptor (EGFR) inhibitors, which are crucial in targeted cancer therapies.
Latest Patents
Hirsch's latest patents include innovative methods for predicting clinical outcomes in patients undergoing treatment with EGFR inhibitors. One of his patents, titled "Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by non-small cell lung cancer patients," discloses methods to obtain an expression score that evaluates gene expression in tissue specimens from cancer patients. This method aims to enhance the understanding of how patients may respond to treatment.
Another significant patent is "Gefitinib sensitivity-related gene expression and products and methods related thereto." This patent identifies a panel of biomarkers that can predict a patient's sensitivity or resistance to gefitinib and other EGFR inhibitors. It describes methods for selecting cancer patients who are likely to benefit from therapeutic administration of EGFR inhibitors and outlines ways to identify molecules that enhance responsiveness to these treatments.
Career Highlights
Fred R. Hirsch is affiliated with the University of Colorado, where he continues to advance research in cancer treatment. His work has been instrumental in developing strategies that improve patient outcomes and personalize cancer therapies.
Collaborations
Hirsch has collaborated with esteemed colleagues such as Paul A. Bunn, Jr. and Wilbur Franklin, contributing to a rich environment of innovation and research in oncology.
Conclusion
Fred R. Hirsch's contributions to cancer research through his patents reflect his commitment to improving treatment options for patients. His innovative methods and collaborations continue to pave the way for advancements in the field of oncology.